迈威生物：前三季度净亏损5.98亿元

Core Insights - Maiwei Biotech (688062.SH) reported a significant increase in revenue for the first three quarters of 2025, achieving 565 million yuan, a year-on-year growth of 301.03% [1] - The company recorded a net loss attributable to shareholders of 598 million yuan [1] - In the third quarter alone, revenue reached 465 million yuan, marking a staggering year-on-year growth of 1717.41% [1] - The performance changes are primarily attributed to substantial revenue recognition from licensing agreements with Qilu Pharmaceutical and DISC, along with a significant increase in drug sales revenue [1]